{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:55Z","timestamp":1793973595992,"version":"4.8.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.radonc.2024.110614","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T23:11:14Z","timestamp":1730934674000},"page":"110614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta\u2010analysis"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-1751","authenticated-orcid":false,"given":"Satoshi","family":"Komiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tsurugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Eriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110614_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2024.110614_b0010","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/hep.32007","article-title":"Comparison of clinical features and outcomes between intrahepatic cholangiocarcinoma and hepatocellular carcinoma in the United States","volume":"74","author":"Lee","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2024.110614_b0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2024.110614_b0020","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cncr.30008","article-title":"Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation","volume":"122","author":"Takeda","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0025","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2024.110614_b0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: An ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ijrobp.2017.02.095","article-title":"Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma","volume":"98","author":"Su","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0040","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1002\/hep.30591","article-title":"Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: A propensity score analysis","volume":"69","author":"Hara","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2024.110614_b0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with Drug-Eluting Beads versus Stereotactic Body radiation therapy for Hepatocellular Carcinoma: Outcomes from a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)","volume":"117","author":"M\u00e9ndez Romero","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1186\/s12885-018-4696-8","article-title":"Comparison of local tumor control in patients with HCC treated with SBRT or TACE: A propensity score analysis","volume":"18","author":"Bettinger","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0060","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2024.110614_b0065","unstructured":"University Hospital medical information network center clinical trial registry, https:\/\/www.umin.ac.jp\/english\/; 1995."},{"key":"10.1016\/j.radonc.2024.110614_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.radonc.2024.110614_b0075","unstructured":"Cochrane Handbook for SystematicReviews of Interventions version 6.4, Chapter 10. Analysing data and undertaking meta-analyses, https:\/\/training.cochrane.org\/handbook\/current\/chapter-10; 2023."},{"key":"10.1016\/j.radonc.2024.110614_b0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1148\/radiol.2016160718","article-title":"Radiation segmentectomy versus TACE Combined with Microwave ablation for unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study","volume":"283","author":"Biederman","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2024.110614_b0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","article-title":"Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma","volume":"29","author":"Biederman","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.radonc.2024.110614_b0090","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820983799","article-title":"Transarterial chemoembolization followed by radiotherapy versus sandwich treatment for unresectable or ablative hepatocellular carcinoma","volume":"19","author":"Lin","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2024.110614_b0095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma","volume":"36","author":"Moreno-Luna","year":"2013","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.radonc.2024.110614_b0100","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1097\/MD.0000000000003015","article-title":"Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: A large-scale, multicenter, propensity Mathching score analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.radonc.2024.110614_b0105","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/OTT.S179247","article-title":"Optimal postoperative adjuvant treatment strategy for HBV-related hepatocellular carcinoma with microvascular invasion: A propensity score analysis","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.radonc.2024.110614_b0110","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12072-022-10339-2","article-title":"Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score matching study","volume":"16","author":"Su","year":"2022","journal-title":"Hep Intl"},{"key":"10.1016\/j.radonc.2024.110614_b0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/COC.0000000000000560","article-title":"Patterns of care and outcomes of definitive external beam radiotherapy and radioembolization for localized hepatocellular carcinoma: A propensity score-adjusted analysis","volume":"42","author":"Bitterman","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00066-015-0929-9","article-title":"Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas","volume":"192","author":"Chan","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2024.110614_b0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fonc.2019.00345","article-title":"Rethinking the role of radiation therapy in the treatment of unresectable hepatocellular carcinoma: A data driven treatment algorithm for optimizing outcomes","volume":"9","author":"Sayan","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12885-019-5461-3","article-title":"Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000487148","article-title":"Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma","volume":"7","author":"Kudo","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1245\/s10434-021-10278-6","article-title":"Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) as a Bridge to Transplant in Unresectable Hepatocellular Carcinoma","volume":"29","author":"Verbus","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0145","doi-asserted-by":"crossref","first-page":"508-","DOI":"10.1200\/JCO.2018.36.4_suppl.508","article-title":"Economic analysis of transarterial chemoembolization (TACE) versus stereotactic body radiotherapy (SBRT) for the treatment of hepatocellular carcinoma (HCC)","volume":"36","author":"Nugent","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1022","article-title":"Unresectable hepatocellular carcinoma treated with radiotherapy and\/or chemoembolization","volume":"96","author":"Chia-Hsien Cheng","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2024.110614_b0160","doi-asserted-by":"crossref","unstructured":"Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Bartl N, Kirste S et al. The Role of Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Hepatocellular Carcinoma Versus Transarterial Chemoembolization (TACE): A Prospective, Non-Randomized Observational Trial (HERACLES). International Journal of Radiation Oncology*Biology*Physics 2019;105.","DOI":"10.1016\/j.ijrobp.2019.06.2058"},{"key":"10.1016\/j.radonc.2024.110614_b0165","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2024.110614_b0170","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1038\/s41598-023-34135-6","article-title":"A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma","volume":"13","author":"Zeng","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2024.110614_b0175","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/0284186X.2021.2009563","article-title":"Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - A systematic review and network meta-analysis of survival data","volume":"61","author":"Chow","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","article-title":"Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma","volume":"105","author":"Shen","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0185","article-title":"Stereotactic Body radiation therapy vs. transarterial chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. Front","author":"Su","year":"202010347","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13014-021-01761-1","article-title":"Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: A systematic review and meta-analysis of observational studies","volume":"16","author":"Long","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: Meta-analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"118","author":"Bae","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0200","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s12029-023-00940-5","article-title":"Stereotactic body radiation therapy with or without transarterial chemoembolization versus transarterial chemoembolization alone in early-stage hepatocellular carcinoma: A systematic review and meta-analysis","volume":"54","author":"Dumago","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0205","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3350\/cmh.2020.0038","article-title":"Stereotactic body radiation therapy for small (\u22645 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial","volume":"26","author":"Yoon","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.radonc.2024.110614_b0210","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.32502","article-title":"A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy","volume":"126","author":"Jang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0215","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/cncr.27533","article-title":"Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization","volume":"118","author":"Kang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2019.12.004","article-title":"Curative irradiation treatment of hepatocellular carcinoma: A multicenter Phase 2 trial","volume":"107","author":"Durand-Labrunie","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110614_b0225","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.prro.2015.02.007","article-title":"Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1\u20132 trial of stereotactic body radiation therapy","volume":"5","author":"Lasley","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.108966","article-title":"Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma","volume":"126","author":"Urbano","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.radonc.2024.110614_b0235","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919866072","article-title":"Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients","volume":"11","author":"Lee","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0240","doi-asserted-by":"crossref","first-page":"482","DOI":"10.5152\/dir.2020.19410","article-title":"Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40\u201375 microns: Assessment of efficacy and safety","volume":"26","author":"Ball\u0131","year":"2020","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.radonc.2024.110614_b0245","first-page":"4625","article-title":"Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma","volume":"18","author":"Cao","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.radonc.2024.110614_b0250","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the precision medicine era: From treatment stage migration to therapeutic hierarchy","volume":"72","author":"Vitale","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.radonc.2024.110614_b0255","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ejrad.2010.12.058","article-title":"Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function","volume":"81","author":"Hsu","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.radonc.2024.110614_b0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000507370","article-title":"A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements","volume":"9","author":"Kudo","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0265","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)","volume":"29","author":"Comito","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.839605","article-title":"Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0275","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.13988","article-title":"Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?","volume":"39","author":"M\u00e4hringer-Kunz","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.radonc.2024.110614_b0280","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12072-021-10173-y","article-title":"Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"15","author":"Li","year":"2021","journal-title":"Hep Intl"},{"key":"10.1016\/j.radonc.2024.110614_b0285","doi-asserted-by":"crossref","first-page":"e19660","DOI":"10.1097\/MD.0000000000019660","article-title":"Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"99","author":"Que","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.radonc.2024.110614_b0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/ajco.13361","article-title":"Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease","volume":"17","author":"Choi","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0295","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jrr\/rrw028","article-title":"Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis\/inferior vena cava tumor thrombosis: Evaluation by comparison with conventional three-dimensional conformal radiotherapy","volume":"57","author":"Matsuo","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2024.110614_b0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/mco.2013.196","article-title":"Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"2","author":"Kang","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0305","doi-asserted-by":"crossref","first-page":"e63864","DOI":"10.1371\/journal.pone.0063864","article-title":"Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and\/or inferior vena cava Tumor Thrombosis","volume":"8","author":"Xi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2024.110614_b0310","doi-asserted-by":"crossref","first-page":"1290691","DOI":"10.3389\/fonc.2023.1290691","article-title":"Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic body radiation therapy or systemic therapy alone","volume":"13","author":"Piening","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0315","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2023.41.4_suppl.489","article-title":"Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC)","volume":"41","author":"Dawson","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0320","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2018.02.031","article-title":"A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma","volume":"129","author":"Su","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110614_b0325","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.radonc.2024.110614_b0330","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/hepr.13595","article-title":"Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study","volume":"51","author":"Kimura","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.radonc.2024.110614_b0335","doi-asserted-by":"crossref","unstructured":"Joo J, Jeon H, Kim D, Kim W, Nam J, Kim D, et al. Predictive power of the albumin-bilirubin score for hepatotoxicity in stereotactic ablative radiation therapy for hepatocellular carcinoma. Cancers (Basel) 2023;15. 10.3390\/cancers15153777.","DOI":"10.3390\/cancers15153777"},{"key":"10.1016\/j.radonc.2024.110614_b0340","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12885-016-2512-x","article-title":"Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma","volume":"16","author":"Que","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110614_b0345","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cam4.1948","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival","volume":"8","author":"Robbins","year":"2019","journal-title":"Cancer Med"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024042762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024042762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:30:41Z","timestamp":1734586241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024042762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":69,"alternative-id":["S0167814024042762"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110614","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta\u2010analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110614"}}